Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer

Prostate cancer (PCa) deaths are typically the result of metastatic castration-resistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral AR inhibitor, was approved for treating patients with mCRPC. Invariably, all PCa patients eventually develop resistance against Enz. Therefore, novel strategies...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Carcinog
Main Authors: Peak, Taylor C., Panigrahi, Gati K, Praharaj, Prakash, Su, Yixin, Shi, Lihong, Chyr, Jacqueline, Rivera-Chávez, José, Flores-Bocanegra, Laura, Singh, Ravi, Vander Griend, Donald J., Oberlies, Nicholas H., Kerr, Bethany A., Hemal, Ashok, Bitting, Rhonda L., Deep, Gagan
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916724/
https://ncbi.nlm.nih.gov/pubmed/31674708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.23129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados